This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Allscripts (MDRX) Declines 1.9% Despite Q3 Earnings Beat
by Zacks Equity Research
Allscripts (MDRX) witnessed decline in core Client Services and Software delivery unit revenues during the third quarter.
AllScripts Healthcare (MDRX) Q3 Earnings Surpass Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of 11.11% and -4.53%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
AllScripts Healthcare (MDRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AllScripts (MDRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allscripts Completes Sale of EPSi Business to Strata
by Zacks Equity Research
Allscripts (MDRX) completes the sale of its EPSi business to Strata. Notably, the combination of two companies can reduce cost associated with healthcare.
3 Sectors Areas to Invest in Ahead of Q3 Earnings
by Urmimala Biswas
Here is a rundown of how sectors like digital health, consumer staple and e-learning have performed in the third quarter of 2020.
MDRX vs. HMSY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MDRX vs. HMSY: Which Stock Is the Better Value Option?
Veeva's Vault eTMF Gets Implemented by Biotest for Trials
by Zacks Equity Research
Veeva's (VEEV) Vault eTMF should enable Biotest to manage all study documents and activities in real time.
The Zacks Analyst Blog Highlights: MDRX, VEEV, DGX, TMO and ZM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MDRX, VEEV, DGX, TMO and ZM
Is Another Great Depression Imminent or Is it Just a Myth?
by Urmimala Biswas
Asian countries have already shown clear signs of major economic recession.
Veeva Vault Picked by AstraZeneca for Quality Management
by Zacks Equity Research
The partnership with AstraZeneca will facilitate end-to-end quality management for Veeva (VEEVA).